International Ophthalmology

, Volume 33, Issue 2, pp 181–183 | Cite as

Acute stroke after intravitreal bevacizumab to treat choroidal neovascularization due to angioid streaks in pseudoxanthoma elasticum

A severe systemic adverse event after an off-label procedure
  • Gianluca Besozzi
  • Andrea Ferrara
  • Enrico Epifani
  • Daniela Intini
  • Margherita Apruzzese
  • Antonio Provenzano
  • Michele Vetrugno
Case Report

Abstract

To report the occurrence of acute stroke after intravitreal bevacizumab administration to treat choroidal neovascularization due to angioid streaks in a patient affected by pseudoxanthoma elasticum. A 54-year-old man with pseudoxanthoma elasticum had vision loss because of choroidal neovascularization due to angioid streaks. He underwent two intravitreal bevacizumab injections. Three days after the second procedure the patient was afflicted by acute stroke. Intravitreal injection of bevacizumab to treat choroidal neovascularization due to angioid streaks in pseudoxanthoma elasticum could lead to severe systemic adverse events.

Keywords

Intravitreal injection Bevacizumab Stroke Angioid streaks 

References

  1. 1.
    Chassaing N, Martil L, Calvas P et al (2005) Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations. J Med Genet 42(12):881–892PubMedCrossRefGoogle Scholar
  2. 2.
    Gass JDM (1997) Angioid streaks. In: Stereoscopic Atlas of Macular Diseases. St. Louis, Mosby, 118–125Google Scholar
  3. 3.
    Gass JDM (2003) Photo essay: “Comet” lesion: an ocular sign of pseudoxanthoma elasticum. Retina 23:729–730PubMedCrossRefGoogle Scholar
  4. 4.
    Clarkson JG, Altman RD (1982) Angiod streaks. Surv Ophthalmol 26:235–246PubMedCrossRefGoogle Scholar
  5. 5.
    Shields JA, Federman JL, Tomer TL, Annesley WH Jr (1975) Angioid streaks. I. Ophthalmoscopic variations and diagnostic problems. Br J Ophthalmol 59:257–266PubMedCrossRefGoogle Scholar
  6. 6.
    Brancato R, Menchini U, Pece A, Davi G, Capoferri C (1978) Laser treatment of macular subretinal neovascularization in angioid streaks. Ophthalmologica 105:299–303Google Scholar
  7. 7.
    Browning AC, Chung AK, Ghanchi F et al (2005) Verteporfin photodynamic therapy of choroidal neovasularization in angioid streaks: one-year results of a prospective casa series. Ophthalmology 112:1227–1231PubMedCrossRefGoogle Scholar
  8. 8.
    Roth DB, Estefanous M, Lewis H (2001) Macular translocation for subfoveal choroidal neovasularization in angioid streaks. Am J Ophthalmol 131:390–392PubMedCrossRefGoogle Scholar
  9. 9.
    Neri P, Salvolini S, Mariotti C, Mercanti L, Celani S, Giovannini A (2009) Long-term control of choroidal neovascularisation secondary to angioid streaks treated with intravitreal bevacizumab (Avastin). Br J Ophthalmol 93(2):155–158PubMedCrossRefGoogle Scholar
  10. 10.
    Myung JS, Bhatnagar P, Spaide RF et al (2010) Long-term outcomes of intravitreal antivascular endothelial growth factor for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina 30:748–755PubMedCrossRefGoogle Scholar
  11. 11.
    Finger RP, Issa PC, Schmitz-Valckenberg S, Holz FG, Scholl HN (2011) Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum. Retina 31:1268–1278PubMedCrossRefGoogle Scholar
  12. 12.
    Dafer RM, SChneck M, Friberg TR (2007) Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol 22:201–204PubMedCrossRefGoogle Scholar
  13. 13.
    Fung AE, Rosenfeld PJ, Reichel E (2006) The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344–1349PubMedCrossRefGoogle Scholar
  14. 14.
    Bhatnagar P, Bailey Freund K, Spaide RF et al (2007) Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina 27:897–902PubMedCrossRefGoogle Scholar
  15. 15.
    Rinaldi M, Dell’Omo R, Romano MR et al (2007) Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks. Arch Ophthalmol 125(10):1422–1423PubMedCrossRefGoogle Scholar
  16. 16.
    Van den Berg JS, Hennekam RC, Cruysberg JR et al (2000) Prevalence of symptomatic intracranial aneurysm and ischaemic stroke in pseudoxanthoma elasticum. Cerebrovasc Dis 10(4):315–319PubMedCrossRefGoogle Scholar
  17. 17.
    Bashshur ZF, Haddad ZA, Schakal AR et al (2009) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 148(1):59–65PubMedCrossRefGoogle Scholar
  18. 18.
    CATT Research Group (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897–1908CrossRefGoogle Scholar
  19. 19.
    IVAN Study Investigators (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119(7):1399–1411CrossRefGoogle Scholar
  20. 20.
    Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273–1279PubMedCrossRefGoogle Scholar
  21. 21.
    Wong TY, Liew G, Mitchell P (2007) Clinical update: new treatments for age-related macular degeneration. Lancet 370(9583):204–206PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Gianluca Besozzi
    • 1
  • Andrea Ferrara
    • 1
  • Enrico Epifani
    • 1
  • Daniela Intini
    • 1
  • Margherita Apruzzese
    • 1
  • Antonio Provenzano
    • 1
  • Michele Vetrugno
    • 1
  1. 1.Anthea HospitalGVM Care and ResearchBariItaly

Personalised recommendations